25 completed, 5 terminated, 2 active not recruiting, 2 recruiting. 37 Phase 1, 12 Phase 2.
Follow neratinib: new trials by email Literature Review of neratinib trials Research Report on neratinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 58 | 2022-10-05 | 2026-11-12 |
| Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test Neratinib, Capmatinib - Metastatic Breast Cancer, Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 10 | 2022-08-18 | 2025-06-11 |
| Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients Neratinib Pill, Fam-Trastuzumab Deruxtecan-Nxki (TDxD) - Gastric Cancer, Gastrointestinal Cancer | Phase 1 | Recruiting | Fox Chase Cancer Center | 18 | 2022-06-24 | 2026-09-21 |
| Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer Neratinib 160 mg, Neratinib 200 mg, Neratinib 240 mg - Advanced Solid Tumor, Ovarian Cancer | Phase 1 | Active not recruiting | Virginia Commonwealth University | 18 | 2020-08-24 | 2026-05-11 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca Neratinib, Divalproex Sodium - Solid Tumor, Adult | Phase 1 / Phase 2 | Suspended | Virginia Commonwealth University | 80 | 2019-05-01 | 2026-10-21 |
| Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer Cyclophosphamide, Doxorubicin, Laboratory Biomarker Analysis - Breast Inflammatory Carcinoma, Locally Advanced Breast Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 34 | 2018-02-19 | 2026-02-12 |
| Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30 - Breast Cancer | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 34 | 2017-12-13 | 2026-10-16 |
| Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation Everolimus, Neratinib, Palbociclib - Advanced Malignant Solid Neoplasm, EGFR Gene Amplification | Phase 1 | Terminated | M.D. Anderson Cancer Center | 84 | 2017-10-31 | 2026-07-22 |
| Safety and Dose Finding Study of Neratinib in Children and Young Adults With Cancer That Has Returned or Not Responded to Treatment Neratinib - Solid Tumor, Central Nervous System Tumor | Phase 1 / Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 14 | 2016-10-01 | 2026-11-04 |
| Phase1 of Neratinib+Trastuzumab, Pertuzumab, Paclitaxel in Patients With Advanced Solid Tumors/HER2+ Neratinib, Paclitaxel, Pertuzumab - Solid Tumor | Phase 1 | Terminated | Michelle Melisko | 6 | 2015-11-03 | 2017-11-17 |
| A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer Neratinib, T-DM1 - Breast Cancer | Phase 1 / Phase 2 | Completed | NSABP Foundation Inc | 49 | 2014-08-01 | 2023-01-26 |
| Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects Lansoprazole, Neratinib - Healthy | Phase 1 | Completed | Puma Biotechnology, Inc. | 15 | 2014-08-01 | 2016-05-11 |
| Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer Cetuximab, Neratinib - Colorectal Cancer | Phase 1 / Phase 2 | Withdrawn | NSABP Foundation Inc | 2013-10-01 | 2021-10-27 | |
| Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib Neratinib - Healthy | Phase 1 | Withdrawn | Puma Biotechnology, Inc. | 2012-08-01 | 2012-05-14 | |
| Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer Paclitaxel, trastuzumab, Neratinib - Breast Cancer | Phase 1 | Completed | NSABP Foundation Inc | 21 | 2011-05-01 | 2014-07-08 |
| Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer Temsirolimus, Neratinib - Breast Cancer | Phase 1 / Phase 2 | Completed | Puma Biotechnology, Inc. | 99 | 2010-04-01 | 2018-09-26 |
| A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor Neratinib, Capecitabine - Advanced Malignant Solid Tumors | Phase 1 | Completed | Puma Biotechnology, Inc. | 7 | 2010-04-01 | 2018-12-19 |
| Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors Neratinib, Vinorelbine - Advanced Malignant Solid Tumors | Phase 1 | Completed | Puma Biotechnology, Inc. | 6 | 2009-07-01 | 2018-06-28 |
| Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib Neratinib - Healthy Subjects | Phase 1 | Completed | Puma Biotechnology, Inc. | 24 | 2009-04-01 | 2012-05-14 |
Showing 20 of 37. Sign in to see all of them.
Breast Neoplasms (14) · Neoplasm Metastasis (4) · Neoplasms (4) · Pancreatic Neoplasms (3) · Anemia (1) · Blast Crisis (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Disease (1) · Disease Progression (1) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Hepatic Insufficiency (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Puma Biotechnology, Inc. (23) · M.D. Anderson Cancer Center (3) · NSABP Foundation Inc (3) · Memorial Sloan Kettering Cancer Center (2) · Virginia Commonwealth University (2) · Fox Chase Cancer Center (1) · Michelle Melisko (1) · National Cancer Institute (NCI) (1) · OHSU Knight Cancer Institute (1)
United States (29) · China (4) · France (4) · Hong Kong (4) · Japan (4) · Spain (3) · Belgium (2) · Canada (2) · Poland (2) · Russia (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Brazil (1) · Croatia (1)
Norman Wolmark, MD (3) · Andrew Poklepovic, MD (2) · Andrew Davis (1) · Chau Dang, MD (1) · Lara Davis, MD (1) · Namrata Vijavergia, MD (1) · Puma Biotechnology (1) · Rachel Layman (1) · Rachel Layman, MD (1) · Sarina A Piha-Paul (1) · Tanya Trippett, MD (1)
PMID 22371427, PMID 22967996, PMID 23632474, PMID 24077916, PMID 24323026, PMID 25287822, PMID 31442103, PMID 33203645, PMID 34482636, PMID 37314501, PMID 37597578, PMID 38650031, PMID 39863139, PMID 41116969
UM1CA186689 (1)